Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00038688 · ClinicalTrials.gov registry record · Phase 3
A Study of Peer Education to Prevent HIV Transmission Among Injection Drug Users and Their HIV Risk Contacts
A Phase 3 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 3
- Development phase
- 2,610
- Enrollment target
NCT00038688: Completed Phase 3 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00038688 is a Phase 3 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 2,610 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (238% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00038688, a Phase 3 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,610 participants
- Enrollment target
Study Summary
Injection drug use is the major mode of HIV transmission in many countries. Injection drug users (IDUs) transmit HIV not only through shared drug injection equipment but also through heterosexual and homosexual transmission and mother-to-child transmission. Studies have shown that peer education programs can reduce HIV risk behavior in IDUs. However, it is not known if reduced HIV risk behavior leads to fewer HIV infections. The purpose of this study is to find out if a peer education program can reduce the number of new HIV infections by changing the behavior of IDUs and their HIV risk contacts.
Interventions
- BEHAVIORAL Peer HIV Education Program
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,610 participants |
| Phase | Phase 3 |
What the finished NCT00038688 record still lists
NCT00038688 is an interventional study that assigns participants to a tested intervention. Its 2,610 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (238% higher).
The record links to 0 conditions, and to 1 intervention - of which Peer HIV Education Program is the first listed.
NCT00038688 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00038688 about?
NCT00038688 is a clinical study titled "A Study of Peer Education to Prevent HIV Transmission Among Injection Drug Users and Their HIV Risk Contacts". Injection drug use is the major mode of HIV transmission in many countries. Injection drug users (IDUs) transmit HIV not only through shared drug injection equipment but also through heterosexual and homosexual transmission and mother-to-child transmission. Studies have shown that peer education pro...
What is the current status of trial NCT00038688?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,610 participants.
What interventions are being tested in trial NCT00038688?
The interventions under investigation include: Peer HIV Education Program (BEHAVIORAL).
Who is sponsoring clinical trial NCT00038688?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00038688's enrollment target sits among peer trials
2,610 84th of 2000 higher than 1,917 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06033950 · 2,600 participants · Phase 3
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists
- NCT06574672 · 2,600 participants · NA
Embedded Palliative Care in the MICU
- NCT06370520 · 2,592 participants
Screening Emotions in Adolescents at the Hospital for mTBI
- NCT06455085 · 2,634 participants · NA
RESTORE: REducing Future fractureS and Improving ouTcOmes of fRagility fracturE